Trouver un autre spécialiste

Louis-Charles Fortier

Directeur de département, Faculté de médecine et des sciences de la santé
FMSS Département de microbiologie et infectiologie

Présentation

Sujets, disciplines ou intérêts de recherche

Clostridium difficile, Clostridioides difficile, Bacteriophages, Prophages, Virulence, Phage genomics, Infectious diseases, Clostridium perfringens, Microbiome, Clostridia, Acinetobacter baumannii, Escherichia coli, Phage therapy

Diplômes

(1996-2001). PhD. Food Science and engineering. Université McGill. Montreal, QC, Canada.

Expériences académiques

Professor. (2007-). Université de Sherbrooke. Sherbrooke, QC, Canada.

Financement

Subvention. Demystifying virus-host interactions in Clostridioides difficile through genetic engineering of bacteriophages and the bacterial S-layer. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2024-2025).
Numéro de subvention : 202309ARB. Voir plus
Subvention. Understanding the interplay between Shp-2 and microbiota in colonic inflammation. Canadian Institutes of Health Research (Ottawa, Canada). 994 500 $. (2023-2028).
Numéro de subvention : 202303PJT. Voir plus
Subvention. Développement d'une surface d'aluminium anodisé pour des applications virucides, bactéricides et sporicides. Natural Sciences and Engineering Research Council (Ottawa, Canada). 135 333 $. (2022-2023).
Numéro de subvention : 567032-2021. Voir plus
Subvention. Phage-host interactions in pathogenic and commensal clostridia. Natural Sciences and Engineering Research Council (Ottawa, Canada). 36 000 $. (2022-2023).
Numéro de subvention : RGPIN-2020-05776. Voir plus
Subvention. Replacement for Anaerobic Workstations. Natural Sciences and Engineering Research Council (Ottawa, Canada). 145 503 $. (2022-2023).
Numéro de subvention : RTI-2023-00302. Voir plus
Subvention. Evaluation de l'efficacite des probiotiques sur les affections post-COVID-19. Canadian Institutes of Health Research (Ottawa, Canada). 997 273 $. (2021-2022).
Numéro de subvention : 202104GA4. Voir plus
Subvention. L'Aluminium anodisé A3S : une surface virucide pour lutter contre la pandémie de COVID-19 dans les hôpitaux, les CHSLD, et les lieux publics. Natural Sciences and Engineering Research Council (Ottawa, Canada). 50 000 $. (2020-2021).
Numéro de subvention : 554629-2020. Voir plus
Subvention. Epithelial-specific role of SOCS1 in prevention of intestinal inflammation. Canadian Institutes of Health Research (Ottawa, Canada). 827 386 $. (2019-2024).
Numéro de subvention : 201809PJT. Voir plus
Subvention. 69th Annual Conference of the Canadian Society of Microbiologists (CSM 2019) - One Health-related symposia. Canadian Institutes of Health Research (Ottawa, Canada). 10 000 $. (2018-2019).
Numéro de subvention : 201809PCS. Voir plus
Subvention. Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection. Canadian Institutes of Health Research (Ottawa, Canada). 398 423 $. (2018-2020).
Numéro de subvention : 201803PJT. Voir plus
Subvention. Isolation and characterization of Clostridium perfringens lytic phages for veterinary applications in the poultry industry. Natural Sciences and Engineering Research Council (Ottawa, Canada). 25 000 $. (2018-2019).
Numéro de subvention : 529295-2018. Voir plus
Subvention. Replacement for Microbial Growth Assay Cluster. Natural Sciences and Engineering Research Council (Ottawa, Canada). 143 350 $. (2018-2019).
Numéro de subvention : RTI-2019-00596. Voir plus
Subvention. Replacement for Fast Protein Liquid Chromatography System. Natural Sciences and Engineering Research Council (Ottawa, Canada). 138 000 $. (2017-2018).
Numéro de subvention : RTI-2018-00630. Voir plus
Subvention. Étude des mécanismes d'action anti-Clostridium difficile par le probiotique Bio-K+. Natural Sciences and Engineering Research Council (Ottawa, Canada). 12 500 $. (2015-2016).
Numéro de subvention : 478094-2015. Voir plus
Subvention. Phage biology and diversity in Clostridium difficile and other commensal clostridia. Natural Sciences and Engineering Research Council (Ottawa, Canada). 150 000 $. (2015-2020).
Numéro de subvention : RGPIN-2015-06334. Voir plus
Subvention. Étude des mécanismes d'action anti-Clostridium difficile par le probiotique Bio-K+. Natural Sciences and Engineering Research Council (Ottawa, Canada). 25 000 $. (2014-2015).
Numéro de subvention : 468586-2014. Voir plus
Subvention. Modulation de l’expression génique par les riborégulateurs: mécanisme d’action et rôle dans la biologie et la virulence de Clostridium difficile. Fonds de Recherche du Québec – Nature et Technologies (Montreal, Canada). 177 222 $. (2014-2017).
Numéro de subvention : 183241. Voir plus
Subvention. Développement d'anticorps spécifiques dirigés contre des protéines de surface des bactéries et des spores de Clostridium difficile et ses toxines. Natural Sciences and Engineering Research Council (Ottawa, Canada). 24 995 $. (2013-2014).
Numéro de subvention : 452900-2013. Voir plus
Subvention. Pathogénèse des infections à Clostridium difficile, interactions hôte-pathogène et développement d'agents thérapeutiques novateurs. Fonds de Recherche du Québec - Santé (Montreal, Canada). 295 451 $. (2012-2016).
Numéro de subvention : 25144. Voir plus
Subvention. Phage biology and diversity in Clostridium difficile. Natural Sciences and Engineering Research Council (Ottawa, Canada). 135 000 $. (2010-2015).
Numéro de subvention : 341450-2010. Voir plus
Subvention. Plateform for studying virulence factors in anaerobic pathogens and for the development of phage-based therapeutic agents. Canada Foundation for Innovation (Ottawa, Canada). 80 276 $. (2009).
Numéro de subvention : 24261. Voir plus
Subvention. Étude moléculaire des bactériophages infectant Clostridium difficile et développement d alternatives thérapeutiques pour traiter la diarrhée associée à C. difficile (DACD). Fonds de Recherche du Québec - Santé (Montreal, Canada). 30 000 $. (2008-2011).
Numéro de subvention : 5854. Voir plus
Subvention. Étude moléculaire des bactériophages infectant Clostridium difficile et développement d alternatives thérapeutiques pour traiter la diarrhée associée à C. difficile (DACD). Fonds de Recherche du Québec - Santé (Montreal, Canada). 196 691 $. (2008-2012).
Numéro de subvention : 14301. Voir plus
Subvention. Development of phage therapy and phage-derived therapeutic molecules to treat Clostridium difficile-associated diarrhea. Canadian Institutes of Health Research (Ottawa, Canada). 195 600 $. (2007-2009).
Numéro de subvention : 200609XNO. Voir plus
Subvention. Culture, molecular typing, and phylogenetic analysis of pathogenic bacteria. Natural Sciences and Engineering Research Council (Ottawa, Canada). 31 500 $. (2007-2008).
Numéro de subvention : grant.2864929. Voir plus
Subvention. Characterization of mobile genetic elements from clostridium difficile and development of molecular tools for genetic manipulations. Natural Sciences and Engineering Research Council (Ottawa, Canada). 72 510 $. (2007-2010).
Numéro de subvention : grant.2933162. Voir plus

Publications

Articles

Alexia L.M. Royer, Émeline Dion, Andrew A. Umansky, Mariano Avino, Olga Soutourina, Louis-Charles Fortier. (2025). Structural determinants of SlpA-mediated phage recognition in Clostridioides difficile. PLOS Pathogens. DOI
Jason S Wilson, Louis-Charles Fortier, Robert P Fagan, Per A Bullough. (2025). Molecular mechanism of bacteriophage contraction structure of an S-layer–penetrating bacteriophage. Life Science Alliance. DOI
(2025). Deciphering the RNA-based regulation mechanism of the phage-encoded AbiF system in Clostridioides difficile. PLOS GENETICS. DOI
(2025). Deciphering the RNA-based regulation mechanism of the phage-encoded AbiF system in Clostridioides difficile. bioRxiv. DOI
(2025). Protection against Clostridioides difficile disease by a naturally avirulent strain. CELL HOST & MICROBE. DOI
(2024). RNA-based regulation in bacteria-phage interactions. ANAEROBE. DOI
Alexia L. M. Royer, Andrew A. Umansky, Marie-Maude Allen, Julian R. Garneau, Maicol Ospina-Bedoya, Joseph A. Kirk, Gregory Govoni, Robert P. Fagan, Olga Soutourina, Louis-Charles Fortier. (2023). Clostridioides difficile S-Layer Protein A (SlpA) Serves as a General Phage Receptor. Microbiology Spectrum. DOI
(2023). Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. BIOMATERIALS ADVANCES. DOI
(2023). Chronic Diarrhea Caused by a Klebsiella oxytoca Toxin Producer Strain Following Antibiotic-Associated Hemorrhagic Colitis: Successful Treatment by Fecal Microbiota Transplant. CLINICAL INFECTIOUS DISEASES. DOI
(2023). Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high-fat/high-cholesterol diet. ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY. DOI
(2023). Interleukin 15 in murine models of colitis. ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY. DOI
(2023). Suspension plasma sprayed copper-graphene coatings for improved antibacterial properties. APPLIED SURFACE SCIENCE. DOI
(2023). The long and sinuous road to phage-based therapy of Clostridioides difficile infections. FRONTIERS IN MEDICINE. DOI
(2023). Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027) Clostridioides difficile. CELL REPORTS. DOI
(2022). High-throughput identification of viral termini and packaging mechanisms in virome datasets using PhageTermVirome (vol 11, 18319, 2021). SCIENTIFIC REPORTS. DOI
(2022). The <italic>Clostridioides difficile</italic> S-Layer Protein A (SlpA) serves as a general phage receptor. bioRxiv. DOI
(2021). Clostridioides difficile phage biology and application. FEMS MICROBIOLOGY REVIEWS. DOI
(2021). High-throughput identification of viral termini and packaging mechanisms in virome datasets using PhageTermVirome. SCIENTIFIC REPORTS. DOI
(2021). Inactivation of the riboswitch-controlled GMP synthase GuaA in Clostridioides difficile is associated with severe growth defects and poor infectivity in a mouse model of infection. RNA BIOLOGY. DOI
(2021). Pathophysiology of Vaginal Erosions in Women Using Pessary: A Pilot Study Examining Vaginal Microbiota. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA. DOI
(2021). Rapid antibacterial activity of anodized aluminum-based materials impregnated with quaternary ammonium compounds for high-touch surfaces to limit transmission of pathogenic bacteria. RSC ADVANCES. DOI
Johann Peltier, Audrey Hamiot, Julian R. Garneau, Pierre Boudry, Anna Maikova, Eliane Hajnsdorf, Louis-Charles Fortier, Bruno Dupuy, Olga Soutourina. (2020). Type I toxin-antitoxin systems contribute to the maintenance of mobile genetic elements in Clostridioides difficile. Communications Biology. DOI
(2020). In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. mBio. DOI
(2020). Type I toxin-antitoxin systems contribute to mobile genetic elements maintenance in Clostridioides difficile and can be used as a counter-selectable marker for chromosomal manipulation. bioRxiv. DOI
(2019). Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. JOURNAL OF CLINICAL MICROBIOLOGY. DOI
(2019). PATHOPHYSIOLOGY OF ULCERATION IN WOMEN USING A PESSARY: AN EXPERIMENTAL APPROACH. INTERNATIONAL UROGYNECOLOGY JOURNAL.
(2018). Bacteriophages Contribute to Shaping Clostridioides (Clostridium) difficile Species. FRONTIERS IN MICROBIOLOGY. DOI
(2018). High Prevalence and Genetic Diversity of Large phiCD211(phiCDIF1296T)-Like Prophages in Clostridioides difficile. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2018). Keyicine: When two heads are better than one to identify an antibiotic !. M S-MEDECINE SCIENCES. DOI
(2018). Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. DOI
(2017). A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. AUTISM RESEARCH. DOI
(2017). Fecal transplants disturb length of pregnancy in a mouse model. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. DOI
(2017). Ileal antimicrobial peptide expression is dysregulated in old age. IMMUNITY & AGEING. DOI
(2017). PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data. bioRxiv. DOI
(2017). PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. SCIENTIFIC REPORTS. DOI
(2017). The Contribution of Bacteriophages to the Biology and Virulence of Pathogenic Clostridia. ADVANCES IN APPLIED MICROBIOLOGY, VOL 101. DOI
(2016). Activation of the IL-1β/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. PLACENTA. DOI
(2016). Characterization of Functional Prophages in Clostridium difficile. CLOSTRIDIUM DIFFICILE: METHODS AND PROTOCOLS, 2ND EDITION. DOI
(2016). End-Gestational Group B Streptococcus Infection: Sex Dichotomic Chorioamnionitis and Autistic-Like Traits in Male Offspring. REPRODUCTIVE SCIENCES.
(2016). Involvement of the IL-1β/PMN/MMP-10 Axis in Group B Streptococcus-Induced Chorioamnionitis. REPRODUCTIVE SCIENCES.
(2015). Cyclic Di-GMP Riboswitch-Regulated Type IV Pili Contribute to Aggregation of Clostridium difficile. JOURNAL OF BACTERIOLOGY. DOI
(2015). Exposition to group B streptococcal maternal inflammation: White matter injury and autistic-like behavior predominantly affecting male rat offspring. INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE. DOI
(2015). Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. CLINICAL INFECTIOUS DISEASES. DOI
(2015). Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile (vol 6, e01112, 2015). MBIO. DOI
(2015). Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile (vol 6, e01112, 2015). MBIO. DOI
(2015). Global Transcriptional Response of Clostridium difficile Carrying the φCD38-2 Prophage. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2015). Group B streptococcus infection during gestation induces gender specific neurodevelopmental impairments. INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE. DOI
Claire Nour Abou Chakra, Allison Mcgeer, Annie-Claude Labbé, Andrew E. Simor, Wayne Gold, Matthew P. Muller, Jeff Powis, Kevin Katz, Julian R. Garneau, Louis-Charles Fortier, Jacques Pepin, Louis Valiquette. (2015). Independent Risk Factors for Recurrence of Clostridium difficile Infection: A Canadian Multicenter Prospective Cohort. Open Forum Infectious Diseases. DOI
(2015). The Clostridium difficile cell wall protein CwpV confers phase-variable phage resistance. MOLECULAR MICROBIOLOGY. DOI
(2014). Characterization of Temperate Phages Infecting Clostridium difficile Isolates of Human and Animal Origins. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2014). Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC INFECTIOUS DISEASES. DOI
(2013). Importance of prophages to evolution and virulence of bacterial pathogens. VIRULENCE. DOI
(2013). White Matter Injury and Autistic-Like Behavior Predominantly Affecting Male Rat Offspring Exposed to Group B Streptococcal Maternal Inflammation. DEVELOPMENTAL NEUROSCIENCE. DOI
(2012). Evidence of In Vivo Prophage Induction during Clostridium difficile Infection. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2012). Novel High-Molecular-Weight, R-Type Bacteriocins of Clostridium difficile. JOURNAL OF BACTERIOLOGY. DOI
(2011). Lack of Association between Clinical Outcome of Clostridium difficile Infections, Strain Type, and Virulence-Associated Phenotypes. JOURNAL OF CLINICAL MICROBIOLOGY. DOI
(2011). Prophage-Stimulated Toxin Production in Clostridium difficile NAP1/027 Lysogens. JOURNAL OF BACTERIOLOGY. DOI
(2011). Role of of gestational inflammation induced by group B streptococcus in perinatal brain lesions and subsequent cerebral palsy. ANNALS OF NEUROLOGY.
(2011). c-di-GMP Turn-Over in Clostridium difficile Is Controlled by a Plethora of Diguanylate Cyclases and Phosphodiesterases. PLOS GENETICS. DOI
(2010). Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC INFECTIOUS DISEASES. DOI
(2010). Novel Riboswitch Ligand Analogs as Selective Inhibitors of Guanine-Related Metabolic Pathways. PLOS PATHOGENS. DOI
Mulhbacher, J., Brouillette, E., Allard, M., Fortier, L.-C., Malouin, F., Lafontaine, D.A. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathogens.
(2009). Antiapoptotic Proteins Bcl-2 and Bcl-XL Inhibit Clostridium difficile Toxin A-Induced Cell Death in Human Epithelial Cells. INFECTION AND IMMUNITY. DOI
Fortier, L.C., Moineau, S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Methods in molecular biology (Clifton, N.J.).
(2008). AbiV, a Novel Antiphage Abortive Infection Mechanism on the Chromosome of Lactococcus lactis subsp cremoris MG1363. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2007). Morphological and genetic diversity of temperate phages in Clostridium difficile. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. DOI
(2006). Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. JOURNAL OF BACTERIOLOGY. DOI
(2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. DRUG METABOLISM AND DISPOSITION. DOI
(2005). Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. JOURNAL OF BACTERIOLOGY. DOI
(2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. HEPATOLOGY. DOI
(2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. DRUG METABOLISM REVIEWS.
(2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. PHARMACOGENETICS. DOI
(2004). UGT1A1 promoter polymorphism as an important determinant of heterocyclic amine detoxification. DRUG METABOLISM REVIEWS.
(2003). Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS MICROBIOLOGY LETTERS. DOI
(2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. DOI
(2002). Acidophilic behaviour of the malolactic bacterium Oenococcus oeni. SCIENCES DES ALIMENTS. DOI
(2000). Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY. DOI
(1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. FEMS MICROBIOLOGY LETTERS. DOI
Tourdot-Maréchal, R., Fortier, L.-C., Guzzo, J., Lee, B., Diviès, C. (1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: A relationship between reduction of ATPase activity and lack of malolactic activity. FEMS Microbiology Letters. DOI
(1998). Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION. DOI

Autres contributions

Cours enseignés à l'UdeS

MCB103 - Microbiologie en pharmacologie - Travaux pratiques. (2023-2025). (3CR).
VIR516 - Projet en virologie. (2025). (1CR).
VIR515 - Virologie - Travaux pratiques. (2023-2024). (1CR).

Divers

Louis-Charles Fortier, Sylvain Moineau. (2009). Phage Production and Maintenance of Stocks, Including Expected Stock Lifetimes. Bacteriophages.